Mode
Text Size
Log in / Sign up
N/A Completed N=89 Randomized Double-blind Treatment

Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear

Source: ClinicalTrials.gov NCT02362724 ↗
Enrolled (actual)
89
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Slit Lamp Findings for Epithelial Edema — 106; 58; 0; 0 Eyes

Summary

The purpose of the study is to compare the investigational contact lens to a marketed contact lens. The study results were not used for design validation of investigational contact lens,

Outcome Measures

OutcomeResultp-value
PRIMARY
Slit Lamp Findings for Epithelial Edema
104; 56; 0; 0; 0; 0
PRIMARY
Slit Lamp Findings for Epithelial Edema
104; 56; 0; 0; 0; 0
PRIMARY
Slit Lamp Findings for Stromal Edema
104; 56; 0; 0; 0; 0
PRIMARY
Slit Lamp Findings for Stromal Edema
104; 56; 0; 0; 0; 0
PRIMARY
Slit Lamp Findings for Corneal Infiltrates
0; 0; 104; 56
PRIMARY
Slit Lamp Findings for Corneal Infiltrates
0; 0; 104; 56
PRIMARY
Slit Lamp Findings for Corneal Vascularization
101; 52; 3; 4; 0; 0
PRIMARY
Slit Lamp Findings for Corneal Vascularization
101; 52; 3; 4; 0; 0
PRIMARY
Slit Lamp Findings for Limbal Hyperemia
76; 44; 28; 12; 0; 0
PRIMARY
Slit Lamp Findings for Limbal Hyperemia
76; 44; 28; 12; 0; 0
PRIMARY
Slit Lamp Findings for Bulbar Hyperemia
70; 42; 33; 14; 1; 0
PRIMARY
Slit Lamp Findings for Bulbar Hyperemia
70; 42; 33; 14; 1; 0
PRIMARY
Slit Lamp Findings for Palpebral Conjunctiva
47; 20; 57; 36
PRIMARY
Slit Lamp Findings for Palpebral Conjunctiva
47; 20; 57; 36
PRIMARY
Slit Lamp Findings for Other Findings
101; 54; 3; 2; 0; 0
PRIMARY
Slit Lamp Findings for Other Findings
101; 54; 3; 2; 0; 0

Eligibility Criteria

Inclusion Criteria

  • Prior to being considered eligible to participate in this study, each subject MUST:
  • Be at least 18 years of age as of the date of evaluation for the study.
  • Have:
  • Read the Informed Consent
  • been given an explanation of the Informed Consent
  • indicated understanding of the Informed Consent
  • signed the Informed Consent document.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  • Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
  • Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
  • Be in good general health, based on his/her knowledge.
  • Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
  • Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
  • To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion Criteria

  • Subjects may not be enrolled in this study if any of the following apply: The subject is currently or has:
  • Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  • Poor personal hygiene.
  • Any active participation in another clinical trial during this trial or within 30 days prior to this study.
  • To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
  • A member, relative or household member of the investigator or of the investigational office staff.
  • Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
  • Previous refractive surgery; or current or previous orthokeratology treatment.
  • Is aphakic or psuedophakic.
  • Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
  • The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
  • The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
  • A history of papillary conjunctivitis that has interfered with contact lens wear.
  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
  • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
  • Pterygium
  • Corneal scars within the visual axis
  • Neovascularization or ghost vessels > 1.0 mm in from the limbus
  • Giant papillary conjunctivitis (GPC) of > Grade 2
  • Anterior uveitis or iritis
  • Seborrheic eczema, seborrheic conjunctivitis or blepharitis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02362724). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search